MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

Meeting: 2018 International Congress

Abstract Number: 307

Keywords: Deep brain stimulation (DBS), MAO-B inhibitors, Wearing-off fluctuations

Session Information

Date: Saturday, October 6, 2018

Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease (PD) and Subthalamic Nucleus Deep Brain Stimulation (DBS).

Background: Safinamide, a monoamino oxidase B and glutamate release inhibitor, demonstrated to be safe and effective for the treatment of motor complications in PD, with a significant improvement in daily ON time without dyskinesias and a significant reduction of levodopa equivalent daily dose (LEDD).

Methods: Nineteen DBS PD patients (mean age 63.5 years ± 9; 7 women, disease duration 15.8 years ± 7), who were prescribed safinamide for motor complications, were evaluated prior to starting the drug, after 6 months and at the last available follow up. Evaluations consisted in: Unified Parkinson’s Disease Scale part III (UPDRS), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (one week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LEDD.

Results: Three patients withdrew safinamide after 3, 6, and 8 months for minor side effects. At the six months evaluation, the remaining 16 PD patients showed a significant improvement of all the scales scores, except for HY, a significant reduction of the daily dosages of all the drugs and of the time spent in OFF and in ON with disabling dyskinesias. At the last evaluation, after a mean time with safinamide of 17.43 months ± 3,6, a significant reduction of daily time spent in OFF and in ON with disabling dyskinesia was still present. As a consequence, the significant reduction of the daily dose of DA and COMT-I. LEDD was not increased and the scale scores remained stable respect to basal values.

Conclusions: Safinamide is safe and effective in improving motor complications of DBS PD patients, maintaing its efficacy on motor complications after 17 months of therapy.

References: Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, Comi C. Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurol Sci. 2018 Feb 13. doi: 10.1007/s10072-018-3272-y. [Epub ahead of print]. Cruz MP. Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson’s Disease. P T. 2017 Oct;42(10):622-637.

To cite this abstract in AMA style:

F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi. Safinamide effect in patients with Parkinson’s disease and deep brain stimulation [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/safinamide-effect-in-patients-with-parkinsons-disease-and-deep-brain-stimulation/. Accessed May 25, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/safinamide-effect-in-patients-with-parkinsons-disease-and-deep-brain-stimulation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley